Get the Stockscreener App
4.84
2.62%
-0.13
After Hours:
4.82
-0.02
-0.41%
Candel Therapeutics Inc stock is traded at $4.84, with a volume of 393.80K.
It is down -2.62% in the last 24 hours and down -18.59% over the past month.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$4.97
Open:
$4.9
24h Volume:
393.80K
Relative Volume:
0.37
Market Cap:
$223.66M
Revenue:
$124.00K
Net Income/Loss:
$-49.99M
P/E Ratio:
-2.8639
EPS:
-1.69
Net Cash Flow:
$-31.03M
1W Performance:
+2.22%
1M Performance:
-18.59%
6M Performance:
-11.27%
1Y Performance:
-24.49%
1-Day Range:
$4.82
$5.00
1-Week Range:
$4.75
$5.25
52-Week Range:
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
4.84 | 223.66M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.50 | 126.09B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.91 | 64.01B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
629.51 | 36.63B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
257.19 | 30.64B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.77 | 27.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-25 | Initiated | Citigroup | Buy |
| Feb-19-25 | Initiated | Canaccord Genuity | Buy |
| Feb-07-25 | Initiated | BofA Securities | Buy |
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
View All
Candel Therapeutics Inc Stock (CADL) Latest News
Geode Capital Management LLC Grows Stock Position in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
S3e01 Life Changing Innovation with Paul Peter Tak, CEO of Candel Therapeutics - iHeart
A new trading data show Candel Therapeutics Inc (CADL) is showing positive returns. - Sete News
Candel Therapeutics to Present Prostate Cancer Trial Data By Investing.com - Investing.com South Africa
Candel Therapeutics to Present Prostate Cancer Trial Data - Investing.com
Candel Therapeutics Announces Oral Presentation of CAN-2409 Data at 2025 ASCO Annual Meeting - Nasdaq
Candel Therapeutics Announces Oral Presentation of Positive - GlobeNewswire
Major Phase 3 Trial Results: Breakthrough Prostate Cancer Treatment Data to be Revealed at ASCO 2025 - Stock Titan
Candel Therapeutics to present Phase 3 prostate cancer data at 2025 ASCO Annual Meeting - Proactive Investors
How To Trade (CADL) - news.stocktradersdaily.com
Critical Review: Candel Therapeutics (NASDAQ:CADL) & ProKidney (NASDAQ:PROK) - Defense World
H.C. Wainwright maintains Buy on Candel Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains Buy on Candel Therapeutics stock - Investing.com Australia
Private Sector Steps Up in Cancer Research as Federal Support Wavers - Baystreet.ca
Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409 - Proactive financial news
Candel Therapeutics Announces Publication of Phase 1b - GlobeNewswire
Candel Therapeutics announces publication of Phase 1b trial data on CAN-2409 - TipRanks
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients - GlobeNewswire
Candel reports positive phase 1b glioma trial results By Investing.com - Investing.com UK
Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI - Proactive financial news
Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI | NASDAQ:CADL - Proactive Investors
Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC - Proactive financial news
Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients - AOL.com
Candel Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CADL - Benzinga
Candel Therapeutics Shares Are Down Today: What's Going On? - Benzinga
Candel Therapeutics Clinical Trial for CAN-2409 Demonstrates Promising Survival Extensions for NSCLC Patients Who Failed Previous Therapies - citybiz
Candel Therapeutics Reports Positive Phase 2a Trial Results - TipRanks
Trading (CADL) With Integrated Risk Controls - news.stocktradersdaily.com
Candel Therapeutics Reports Both Prolonged Median Overall - GlobeNewswire
Candel Therapeutics Reports Final Phase 2a Survival Data for Lung Cancer Treatment - MarketScreener
Candel Therapeutics Reports Both Prolonged Median Overall Survival And Long Tail Of Survival In Phase 2A Clinical Trial Of CAN-2409 In Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive To Immune Checkpoint Inhibitor (ICI) Treat - MarketScreener
Candel Therapeutics reports positive survival data for CAN-2409 in advanced lung cancer trial - Proactive Investors
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatm - The Manila Times
Breakthrough: Cancer Drug CAN-2409 Achieves 24.5-Month Survival in Advanced Lung Cancer Patients - Stock Titan
Small cap wrap: Nano One Materials, EnWave, Summit Therapeutics... - Proactive financial news
Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now - Zacks Investment Research
CADLCandel Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Candel therapeutics CEO sells $229,624 in stock By Investing.com - Investing.com Canada
Insider Sell Alert: Paul Tak Sells 26,172 Shares of Candel Thera - GuruFocus
Candel therapeutics chief scientific officer sells $281,672 in stock By Investing.com - Investing.com South Africa
Candel Therapeutics’ chief medical officer sells $396,995 in stock By Investing.com - Investing.com Canada
Candel therapeutics CEO sells $229,624 in stock - Investing.com India
Candel Therapeutics Executives Sell Shares Under Trading Plans - TradingView
Candel Therapeutics’ chief medical officer sells $396,995 in stock - Investing.com
Small cap wrap: Santacruz Silver, GoviEx Uranium, Candel Therapeutics... - Proactive Investors
Candel Therapeutics Partners With IDEA Pharma To Advance CAN-2409 Cancer Immunotherapy - Nasdaq
Candel Therapeutics partners with IDEA Pharma on commercialization of CAN-2409 - Proactive Investors
Candel Therapeutics Partners With IDEA Pharma for CAN-2409 Commercialization -March 20, 2025 at 08:29 am EDT - MarketScreener
Candel Therapeutics and IDEA Pharma Announce Strategic - GlobeNewswire
Breakthrough Prostate Cancer Drug Shows 30% Better Results as Candel Secures Key Partnership - Stock Titan
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
2.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):